The vascular malformations market was valued at USD 2.98 Billion in 2024, driven by the growing advancements in imaging technologies across the 8 major markets. The market is anticipated to grow at a CAGR of 6.50% during the forecast period of 2025-2034, with the values likely to reach USD 5.59 Billion by 2034.
Galderma Pharma S.A.
Headquartered in Lausanne, Switzerland, Galderma Pharma S.A. was established in 1981. Galderma's portfolio specialises in dermatology and includes injectables and devices for reducing wrinkles and other skin concerns.
Other key players in the market include Sirtex Medical Limited.
This product will be delivered within 3-5 business days.
Vascular Malformations Market Overview
Vascular malformations are abnormal growths of blood vessels that can occur in various parts of the body, leading to the formation of a network of dilated vessels. These malformations can be present at birth or develop later in life and may cause symptoms like swelling, pain, and bleeding. Treatment options include surgery, sclerotherapy, and laser therapy, depending on the type and location.Vascular Malformations Market Growth Drivers
Genetic Disorder Research Expands Treatment Options for Vascular Malformations
The increasing focus on precision medicine and the rise in genetic disorder research are key drivers of growth in the vascular malformations market. Advances in genetic research and treatment development for rare conditions, such as vascular malformations, have accelerated over recent years, bringing new treatment options to the forefront. For instance, in July 2024, a study demonstrated the potential of the anticancer drug sotorasib for treating arteriovenous malformations (AVMs) caused by mutations in the KRAS gene. Sotorasib, used for treating non-small cell lung cancer, showed promising effects in preclinical models, preventing the development of vascular malformations. This breakthrough suggests that sotorasib could provide a novel therapeutic avenue for patients with severe AVMs, potentially driving market growth for treatments targeting genetic vascular malformations during the forecast period.Surge in Advanced Research and Development Initiatives to Boost Vascular Malformations Market Demand
The growing adoption of innovative experimental models and genetic research into vascular disorders is expected to drive significant development in the vascular malformations market. The creation of models that mimic specific vascular malformations enables more accurate preclinical testing and targeted therapies. For instance, in February 2023, a research team from the University of North Carolina developed a microfluidic model that mimics a rare genetic disorder affecting blood and lymphatic vessels. The model focuses on PIK3CA-activating mutations, a gene responsible for various vascular malformations. By providing a more precise model for understanding these rare disorders, the research could pave the way for new treatments targeting PIK3CA-related vascular malformations. This advancement is expected to further stimulate market development, driving demand for more targeted therapies and innovations in the coming years.Vascular Malformations Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:Increased Focus on Non-Invasive Treatment Modalities
Non-invasive treatments, such as laser therapy and sclerotherapy, are gaining traction in the vascular malformations market due to their reduced recovery times and fewer complications compared to traditional surgical approaches. This shift towards minimally invasive procedures is expected to drive market growth as patients seek effective, less invasive solutions for managing vascular malformations.Advancements in Imaging Technologies to Boost Vascular Malformations Market Value
The adoption of advanced imaging technologies, including MRI and ultrasound, is improving the diagnosis and treatment of vascular malformations. These technologies enable more precise identification of lesion locations and sizes, allowing for personalised treatment plans. The increasing availability and accuracy of diagnostic tools are expected to boost the market by enhancing clinical outcomes and treatment efficacy.Rising Awareness and Early Diagnosis to Meet Increasing Vascular Malformations Market Demand
As awareness of vascular malformations increases, earlier diagnosis and treatment become more common. Greater public and healthcare provider awareness of symptoms, such as visible birthmarks or swelling, is leading to earlier interventions. This trend is anticipated to drive market growth by reducing complications and improving long-term outcomes for patients.Growing Demand for Targeted Therapies in Vascular Malformation Treatment
There is a growing demand for targeted therapies and biologics in the treatment of vascular malformations. These therapies offer higher precision and better patient outcomes compared to traditional treatments, contributing to an expanding market. The focus on innovative treatments, such as gene therapy and targeted anti-VEGF drugs, is likely to dominate the market development in the coming years.Vascular Malformations Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Capillary Vascular Malformations
- Venous Malformations
- Spider Angiomas
- Pyogenic Granulomas
- Angiofibromas
- Hemangioma
- Others
Market Breakup by Drugs
- Sirolimus
- Sodium Tetradecyl Sulfate
- Ethanol
- Others
Market Breakup by End User
- Hospital
- Homecare
- Specialty Clinics
- Others
Market Breakup by Region
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
- India
Vascular Malformations Market Share
Market Segmentation Based on Drugs to Witness Significant Growth
The Sirolimus segment is estimated to lead the market share by drugs, due to its proven efficacy in treating complex vascular lesions. Sirolimus, an immunosuppressive drug, helps reduce the size of these malformations and is widely used for conditions like lymphatic malformations. Its ability to effectively manage symptoms and prevent further complications positions it as the most popular choice. The segment’s dominance is further supported by ongoing clinical studies and a growing understanding of its mechanism of action in treating vascular malformations.Vascular Malformations Market Analysis by Region
The United States dominates the market due to its advanced healthcare infrastructure, high treatment demand, and the presence of key players in the medical device and pharmaceutical sectors. Additionally, the strong adoption of innovative therapies, high healthcare spending, and well-established reimbursement policies contribute to its market leadership. The increasing prevalence of vascular malformations and the availability of advanced diagnostic and therapeutic options further fuel the market's growth in the US during the forecast period.Leading Players in the Vascular Malformations Market
The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:Galderma Pharma S.A.
Headquartered in Lausanne, Switzerland, Galderma Pharma S.A. was established in 1981. Galderma's portfolio specialises in dermatology and includes injectables and devices for reducing wrinkles and other skin concerns.
Novartis AG
Founded in 1996 and headquartered in Basel, Switzerland, Novartis AG is a global healthcare company. It offers a broad portfolio of innovative medicines, including treatments for oncology, immunology, ophthalmology, and neuroscience. Novartis is also active in the cardiovascular, dermatology, and respiratory markets, providing a comprehensive range of healthcare solutions.Bayer AG
Bayer AG, established in 1863 and based in Leverkusen, Germany, is a leading global pharmaceutical and life sciences company. Its diverse portfolio includes medications for oncology, cardiology, and women's health, along with dermatology and ophthalmology treatments. Bayer also provides agricultural solutions, veterinary products, and consumer health goods.Cook Medical LLC
Cook Medical LLC, established in 1963 and headquartered in Bloomington, Indiana, USA, is a prominent medical device manufacturer. The company offers a wide range of products for interventional radiology, urology, cardiology, and vascular care. Cook Medical focuses on innovative solutions for minimally invasive procedures across several medical specialities.Other key players in the market include Sirtex Medical Limited.
Key Questions Answered in the Vascular Malformations Market
- What was the vascular malformations market value in 2024?
- What is the vascular malformations market forecast outlook for 2025-2034?
- What is the market breakup based on the type?
- What is the market breakup based on the drugs?
- What is the market breakup based on the end user?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major vascular malformations market trends?
- Which type will lead the market segment?
- Which drugs will lead the market segment?
- Which end user will lead the market segment?
- Who are the key players involved in the venous ulcer market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Vascular Malformations Market Overview - 8 Major Markets
4 Vendor Positioning Analysis
5 Vascular Malformations Overview
6 Patient Profile
7 Vascular Malformations Market - Epidemiology Scenario and Forecast - 8 Major Markets
8 Vascular Malformations Market Landscape - 8 Major Markets
9 Vascular Malformations Market Challenges and Unmet Needs
11 Vascular Malformations Market Dynamics
12 Vascular Malformations Market Segmentation (218-2034) - 8 Major Markets
13 United States Vascular Malformations Market (218-2034)
14 United Kingdom Vascular Malformations Market (218-2034)
15 Germany Vascular Malformations Market (218-2034)
16 France Vascular Malformations Market (218-2034)
17 Italy Vascular Malformations Market (218-2034)
18 Spain Vascular Malformations Market (218-2034)
19 Japan Vascular Malformations Market
20 India Vascular Malformations Market
21 Regulatory Framework
22 Patent Analysis
23 Clinical Trials Analysis
24 Grants Analysis
25 Funding and Investment Analysis
26 Strategic Initiatives
27 Supplier Landscape
28 Vascular Malformations Market - Distribution Model (Additional Insight)
30 Payment Methods (Additional Insight)
Companies Mentioned
- Galderma Pharma S.A.
- Novartis AG
- Bayer AG
- Cook Medical LLC
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 400 |
Published | June 2025 |
Forecast Period | 2025 - 2034 |
Estimated Market Value ( USD | $ 2.98 Billion |
Forecasted Market Value ( USD | $ 5.59 Billion |
Compound Annual Growth Rate | 6.5% |
Regions Covered | Global |
No. of Companies Mentioned | 4 |